Drug discovery and development in idiopathic pulmonary fibrosis: the changing landscape.

Autor: Cruwys S; TherapeutAix UG, Juttastrasse 18, 52066 Aachen, Germany., Hein P; TherapeutAix UG, Juttastrasse 18, 52066 Aachen, Germany., Humphries B; TherapeutAix UG, Juttastrasse 18, 52066 Aachen, Germany., Black D; TherapeutAix UG, Juttastrasse 18, 52066 Aachen, Germany. Electronic address: darcey@therapeutaix.com.
Jazyk: angličtina
Zdroj: Drug discovery today [Drug Discov Today] 2024 Nov; Vol. 29 (11), pp. 104207. Date of Electronic Publication: 2024 Oct 11.
DOI: 10.1016/j.drudis.2024.104207
Abstrakt: Idiopathic pulmonary fibrosis (IPF) is an area of high unmet clinical need and high research activity in the pharmaceutical and biotech industries. The two approved therapies, nintedanib and pirfenidone, have issues with efficacy and tolerability. Despite a considerable number of development programs reaching late-stage Phase 2b or 3 clinical trials, no drug other than nintedanib and pirfenidone has successfully demonstrated a benefit for patients. An analysis of these failures, and consideration of the trajectories of some of the current development projects, may offer novel paradigms for choosing modes-of-action and for the development of successful drugs.
(Copyright © 2024 Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: